Will Rua Life Sciences stock go up?

According to Danelfin AI, Rua Life Sciences has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (50.13%) is +0.54% vs. the average probability (49.60%) of all European stocks.

Is it a good time to buy, sell, or hold Rua Life Sciences stock right now?

Rua Life Sciences has today a Hold rating (AI Score 6/10), according to Danelfin AI. Its probability of beating the market in 3 months (50.13%) is +0.54% vs. the average probability (49.60%) of all European stocks, based on our AI-powered analysis. You can find more details on whether Rua Life Sciences stock is a good buy .

What is going on with Rua Life Sciences stock in the last 3 months?

The Rua Life Sciences stock performance in the last quarter has been -.

Does Rua Life Sciences offer dividend payments?

No, Rua Life Sciences does not currently pay dividends.

What is the current market capitalization of Rua Life Sciences?

Rua Life Sciences's market cap is GBX 11.79M, as of 2026-07-03 08:00.

Rua Life Sciences PLC (RUA.L) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

RUA.L AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score

Hold

Rua Life Sciences (RUA.L) has an AI Score of 6/10 (Hold) because, according to an overall analysis, it has a probability advantage of +0.54% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.60%) and the probability of RUA.L (50.13%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.60%
RUA.L probability advantage of beating the market (3M)+0.54%
RUA.L probability of beating the market (3M)50.13%

RUA.L probability advantage of beating the market (3M): +0.54%

The AI-powered overall analysis of Rua Life Sciences (RUA.L) is based on the 0 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of RUA.L:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
-	-	-	-	-

RUA.L probability advantage of beating the market (3M)Total:+0.54%
RUA.L AI Score

Significant changes Vs previous day

RUA.L Trading Parameters

Trading parameters are unavailable for RUA.L.

RUA.L Frequently Asked Questions

Will Rua Life Sciences stock go up?
According to Danelfin AI, Rua Life Sciences has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (50.13%) is +0.54% vs. the average probability (49.60%) of all European stocks.
Is it a good time to buy, sell, or hold Rua Life Sciences stock right now?
What is going on with Rua Life Sciences stock in the last 3 months?
Does Rua Life Sciences offer dividend payments?
What is the current market capitalization of Rua Life Sciences?

Rua Life Sciences PLC Company Profile

Rua Life Sciences PLC (RUA.L) is a leading innovator in the medical device and biomaterials sector, dedicated to improving patient outcomes through advanced cardiovascular technologies. The company specializes in the design, development, and manufacture of implantable medical devices and high-performance biomaterials, addressing critical needs within the global healthcare market. With a strategic focus on cardiovascular health, Rua Life Sciences aims to provide solutions that enhance the longevity and quality of life for patients suffering from heart and vascular conditions. Its commitment to pioneering new approaches positions it as a key player in a rapidly evolving industry.

At the core of Rua Life Sciences' innovation lies its proprietary polymer technology, which forms the foundation for its next-generation medical components. Through extensive research and development, the company engineers biomaterials that offer superior biocompatibility, durability, and performance, crucial attributes for long-term implantable devices. This technological edge enables the creation of advanced solutions for complex cardiovascular challenges, including the development of artificial heart valves, vascular grafts, and other critical components. Rua Life Sciences' scientific rigor ensures that its products meet the highest standards of safety and efficacy, driving progress in medical science.

Rua Life Sciences maintains a significant strategic advantage through its integrated capabilities, spanning from fundamental material science expertise to sophisticated device manufacturing. This comprehensive approach allows the company to exert stringent quality control across the entire product lifecycle, from initial concept to final production, while also accelerating development timelines. A robust intellectual property portfolio further strengthens its market position, protecting its innovative technologies and providing a competitive moat. Established regulatory pathways and a deep understanding of compliance requirements facilitate efficient market entry and expansion for its life-saving products.

The company is well-positioned for substantial growth within the expanding global medical device market, driven by an aging population and increasing demand for advanced cardiovascular treatments. Rua Life Sciences' commitment to innovation and its proven ability to translate scientific breakthroughs into commercially viable products offer a compelling value proposition for investors. As it continues to bring transformative technologies to patients worldwide, the company aims to deliver significant returns while making a profound impact on global health. Its revenue mix is primarily derived from biomaterial sales and licensing agreements, with a go-to-market strategy that combines direct sales to key partners and a network of specialized distributors, ensuring a global presence across North America, Europe, and Asia.

Sector:
Country:United Kingdom
Industry:
Address:2 DRUMMOND CRESCENT, Ayrshire
Employees:40
Website:rualifesciences.com

Pros

High regulatory barriers to entry for implantable devices

Aging global demographics driving demand for cardiovascular implants

Proprietary biomaterial technology for medical implants

Established clinical adoption leading to surgeon familiarity

Critical nature of products allowing for pricing power

Cons

Extensive and costly clinical trial requirements for new products

Exposure to product liability claims and litigation risk

Reimbursement pressures from national healthcare systems

Dependency on specialized manufacturing processes and facilities

Risk of technological disruption from less invasive procedures

Pros

Cons

Company

AI Score

Compare

QLIFE.STQlife Holding AB

BMX.WABioMaxima SA

BRETEC.HEBioretec Oy

LIFE.OLLifecare ASA

AMS.LAdvanced Medical Solutions Group PLC

Company

AI Score

Compare

RUA.L Top 10 Industry Stocks

Health Care Equipment & Supplies

	Company	AI Score	Compare
1	PRM.MCPrim SA
2	VBSN.SWIVF Hartmann Holding AG
3	ALSGD.PASpineguard SA
4	OTO.MIOtofarma SpA
5	MRC.WAMercator Medical SA
6	MOVE.SWMedacta Group SA
7	LXB.STLuxbright AB
8	PHH2.FPaul Hartmann AG
9	RUA.LRua Life Sciences PLC
10	EL.PAEssilorLuxottica SA

	Company	AI Score	Compare

RUA.L Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	FAE.MCFaes Farma SA
2	REC.MIRecordati Industria Chimica e Farmaceutica SpA
3	ALK B.COALK-Abello A/S
4	ANCR.LAnimalcare Group plc
5	MPARK.E.ISMLP Saglik Hizmetleri AS
6	PRM.MCPrim SA
7	DMP.DEDermapharm Holding SE
8	TRILC.E.ISTurk Ilac ve Serum Sanayi AS
9	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
10	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS

	Company	AI Score	Compare

RUA.L Stock AI Analysis